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Context
The fibrotic interstitial lung diseases (ILDs) 
encompass a heterogenous group of conditions 
affecting the lung parenchyma, resulting in 
progressive, irreversible scarring. While prognosis 
varies between conditions, they commonly have a 
significant adverse impact both on health-related 
quality of life (HRQoL) and on survival. For idiopathic 
pulmonary fibrosis (IPF), the most common and 
fatal ILD, antifibrotic therapies (nintedanib [1] and 
pirfenidone [2]) have been shown to slow rate of 
progression, but the disease remains incurable. 
Management of all fibrotic ILDs therefore requires 
symptomatic and supportive care as well as 
interventions aimed at modifying the disease 
course [3].
Progressive fibrotic ILD causes cumulative 
impairment in gas transfer, with resultant 
desaturation and dyspnoea on exertion, even 
if oxygen saturations are acceptable at rest. As 
the disease progresses, even simple activities of 
daily living can be limited by severe dyspnoea, 
significantly impacting HRQoL. A small number 
of studies have been undertaken to investigate 
the effect of effect of supplemental oxygen on 
exercise performance in ILD, with a Cochrane 
review concluding that there was insufficient 
evidence to support or refute ambulatory oxygen 
therapy (AOT) or short-burst oxygen therapy in 
patients with exercise-induced desaturation [4]. 
However, none of the three studies included in 
this review nor two subsequent publications [5, 6] 
looked at HRQoL as an outcome, focusing instead 
on physiological parameters in a laboratory 
environment.
HRQoL refers to subjective experiences reported 
by the patient. It can be formally assessed using 
a variety of tools that have been developed for 
use in respiratory conditions (e.g. the St George’s 
Respiratory Questionnaire (SGRQ)) [7] or in ILD 
specifically (e.g. King’s Brief Interstitial Lung 
Disease Health Status Questionnaire (K-BILD) 
[8]). These assess self-reported patient experience 
across a variety of domains (e.g. chest symptoms, 
psychological, breathlessness and activity). They 
are of increasing interest as a research outcome 
as it is recognised that interventions that improve 
objective markers of disease progression (including 
antifibrotic therapy in IPF) may not improve 
quality of life. Research is therefore needed into 
interventions that improve quality of life in advanced 
fibrotic ILD.
The AmbOx study [9] was designed to investigate 
the impact of AOT on HRQoL in patients with 
fibrotic ILD.
Commentary on:
Visca D, et al. Effect of ambulatory oxygen on 
quality of life for patients with fibrotic lung 
disease (AmbOx): a prospective, open label, 
mixed-method, crossover randomised controlled 
trial. Lancet Respir Med 2018; 6: 759–770.
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Methods
This was a prospective randomised control trial (RCT) 
performed across three centres in the UK. It involved 
patients aged ≥18 years with a fibrotic interstitial 
lung disease, who were not hypoxic at rest (resting 
saturations >94%) but had exercise-induced 
desaturation, defined as a fall in transcutaneous 
oxygen saturations to ≤88% on a 6-min walk test 
(6MWT). The study used a crossover design with 
patients randomly allocated to either AOT or no 
intervention for a period of 2 weeks, after which 
they swapped to the other arm. For the trial itself, 
there was no placebo control or blinding. However, 
for the baseline 6MWT performed at the start of the 
trial, placebo air was used for those randomised to 
the control group, with labels on the gas cylinders 
covered to ensure blinding of participants.
The primary outcome of the study was HRQoL 
as measured by the K-BILD questionnaire, with 
a minimal clinically important difference (MCID) 
considered to be 8 (total score range for the 
questionnaire 0–100). A K-BILD questionnaire 
was completed by all participants at baseline, the 
end of the first 2-week trial block and at the end 
of the second 2-week trial block after crossover of 
treatment arms. A variety of secondary outcomes 
were also examined. These included other self-
reported outcome questionnaires: the University 
of California San Diego Shortness of Breath 
Questionnaire, the SGRQ and the Hospital Anxiety 
and Depression Scale (HADS). Patients were given 
personal activity monitors to investigate whether 
ambulatory oxygen was associated with increased 
physical activity levels. The results for the baseline 
6MWT, performed on either oxygen or placebo air, 
were also reported.
Main results
84 patients were randomised, with 41 allocated to 
oxygen first and 43 to no oxygen. These groups were 
well matched at baseline, with no difference in age 
and sex distribution, lung function, cardiac function 
or performance on 6MWT. IPF accounted for a 
similar proportion of fibrotic ILD cases in both arms 
(56% and 60%, respectively) and there were no 
significant differences in K-BILD scores (the primary 
outcome of the study) at baseline (mean 51.2 in 
the oxygen first arm and 49.7 in the no oxygen first 
arm). As would be expected from a study in this 
patient population, participants had moderate to 
severe restrictive lung disease, with mean diffusing 
capacity of carbon monoxide of 39.8% and 37.3% 
predicted, and a forced vital capacity of 71.1% and 
75.1% predicted in the oxygen first and no oxygen 
first arms, respectively.
The first question the study investigated 
was the effect of oxygen on performance in the 
6MWT. This was performed as a blinded placebo-
controlled trial, with air-filled cylinders used in the 
placebo arm. Patients on oxygen walked nearly 
20 m further than those on air (373.2 m versus 
354.7 m, p=0.001) and had significantly shorter 
oxygen saturation recovery time measured by pulse 
oximetry (117 s versus 217.7 s, p<0.0001). They 
also had significantly lower Borg dyspnoea and 
fatigue scores, as well as faster Borg score recovery 
times (112 s versus 171 s, p=0.0008).
Although the results of the 6MWT suggest a 
physiological benefit of supplemental oxygen during 
exertion, that does not necessarily correspond to 
the main focus of this study: quality of life. The 
primary outcome of the investigation was HRQoL 
assessed by the K-BILD score. This is composed of 
three components (breathlessness and activities, 
chest symptoms, and psychological symptoms) 
as well as an overall score. It is scored out of 100, 
with higher scores reflecting better HRQoL. There 
was a statistically significant improvement in 
breathlessness and activities (mean 44.4 versus 
35.8, p<0.0001), chest symptoms (mean 65.5 
versus 57.9, p=0.009) and total scores (mean 
55.5 versus 51.8, p<0.0001) in the AOT arm, with 
no improvement in psychological symptoms (mean 
55.2 versus 52.8, p=0.12). However, although the 
differences were statistically significant, the mean 
difference in the total score was small (3.7 out of 100).
The study also looked at two other patient 
outcome scores. The SGRQ, a general respiratory 
HRQoL tool (scored out of 100, with lower scores 
reflecting better HRQoL), similarly showed small but 
statistically significant improvement in the Activity 
(61.5 versus 68.9, p=0.003) and Total (48.7 versus 
52.4, p=0.018) components, but no difference in 
the Symptoms section (53.3 versus 54.9, p=0.51). 
There were no differences between oxygen and 
non-oxygen treated patients in the Depression and 
Anxiety components of the HADS.
The study also used patient activity monitors to 
investigate whether ambulatory oxygen correlated 
with increased levels of activity. These results were 
available for 41 patients, and demonstrated no 
difference in activity levels or step counts between 
the ambulatory oxygen and no oxygen periods 
(mean 5277 steps per day on oxygen versus 4799 
on no oxygen, p=0.19).
Commentary
There is a paucity of evidence for interventions 
that improve HRQoL in ILD. This study therefore 
represents an important step not only in providing 
evidence-based recommendations for interventions 
that address this but also in demonstrating that 
HRQoL can be used as a primary outcome in a RCT 
in this disease. However, there are some limitations, 
both in the design of the study and in the findings.
Firstly, apart from the initial 6MWT, this study 
was not placebo controlled. This study design is 
reasonable, as the provision of dummy air-filled 
canisters and accompanying paraphernalia may 
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place an unfair burden on participants. However, it 
does make it difficult to determine what effect was 
due to oxygen and what due to placebo. Conversely, 
since HRQoL was the primary outcome, and the 
logistical, social and psychological burden of home 
oxygen therapy may itself adversely impact patient 
well-being [10], the study design is appropriate for 
looking at overall patient experience with AOT.
A second limitation is the short length of the 
crossover periods, which means we are unable to 
determine whether quality of life differences persist 
beyond the 2-week study period. The HOT-HMV trial 
of home noninvasive ventilation (NIV) in chronic 
obstructive pulmonary disease, another trial that 
involved bringing medical equipment into the home 
environment, showed an initial improvement in 
HRQoL in the NIV arm, which disappeared beyond 
month 3 [11]. Longer-term follow up is needed to 
see whether the improvement seen in AmbOx is 
maintained.
While AmbOx did yield a positive outcome for 
the AOT arm, the real-world clinical significance 
we can extract from these results also needs 
to be considered. Firstly, although there was a 
statistically significant difference in total K-BILD 
score, this difference was small (only 3.7) and 
well below the previously reported MCID of 8 [12]. 
The authors address this, citing evidence that 
in more severe disease (as in the AmbOx study 
population), a difference of 4 is clinically significant 
[9]. Regardless of the exact numbers, the small but 
positive improvements in HRQoL should inform 
discussions with patients when choosing whether 
or not to have AOT.
Of the three components of the K-BILD score, 
the biggest difference between the AOT and control 
arms was in Breathlessness and Activities, where 
a mean difference of 8.6 was noted. It is therefore 
surprising, as well as somewhat disappointing, to 
see that the data from the activity monitors showed 
no increase in activity levels in the AOT arm. The 
reasons for this are not clear but it suggests that 
drivers and limitations of “activity” in advanced 
ILD are complex. Other interventions, such as 
pulmonary rehabilitation, may play a bigger role 
here, and there is a current study (HOPE-IPF) 
investigating whether oxygen supplementation 
may enhance exercise training in IPF [13].
A final notable result from the study is that only 
67% of patients chose to continue using AOT at 
the end of the trial. Unsurprisingly, patients who 
reported higher improvements in breathlessness 
and walking ability with AOT were more likely to 
choose to continue. The fact that a third of patients 
did not wish to continue using AOT demonstrates 
the limitations of this intervention in ILD and this 
should again inform conversation with patients 
regarding the decision to start home oxygen.
Implications for practice
The AmbOx trial provides RCT evidence for AOT 
providing a small but significant benefit in HRQoL in 
patients with advanced fibrotic ILD. Given the paucity 
of other interventions, this should be recognised 
and should prompt clinicians to consider this for 
their patients. When discussing this, clinicians can 
be positive about the beneficial effects identified, 
but given the results of the study, discussions 
should be tempered by realism: improvements are 
likely to be small, and there is a logistical, social 
and psychological burden associated with home 
oxygen therapy [10]. Furthermore, given that this 
study found that AOT itself did not lead to increased 
activity levels, the provision of AOT should not be 
considered sufficient in itself; other interventions, 
such as pulmonary rehabilitation and addressing 
co-existing depression or anxiety, remain essential 
in the management of fibrotic ILD.
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